QUISTES EPIDÉRMICOS O QUERATINIZANTES

1. Elder D, Elenitsas R, Jaworsky C, Johnson B. Histopathology of the Skin. Philadelphia, New York. Lippincott-Raven 1997.
2. Fitzpatrik T, Eisen A, Wolf K,Freedberg, Austen F. Dermatology in General Medicine. New York Fourth Edition. McGraw-Hill, Inc 1993.
3. Saúl A. Lecciones de Dermatología. México. 2001, 14º edición. p. 623.

NEVOS MELANOCÍTICOS

1. Aristimuño M, Peniche J. Frecuencia de nevos melanocíticos en la población mexicana. Dermatol Rev Mex 1990; 34:347-354.
2. Blessing K. Benign atypical naevi: diagnostic difficulties and continued controversy. Histopathology 1999;34: 189-198.
3. Cabrera H. Nevo melanocítico congénito. Una forma particular: El nevo dividido palpebral. Arch Argent Dermatol 1996;46:137-140.
4. Fitzpatrick TB, Eisen AZ, Wolff K, et al. Dermatology in General Medicine. New York:Mc Graw-Hill, 1993: 996-1077.
5. Friedman R, Rigel S, Kopf A, et al. Cáncer de piel. Buenos Aires: Panamericana, 1993.
6. Jiménez F. Nevos de células névicas. Rev Cent Dermatol Pascua 1998; 7(2):90-93.
7. Lever W, Schamburg-Lever G. Histopatología de la piel. Buenos Aires:
Interamericana 1991:681-719.
8. Magaña M. Nevo melanocítico congénito. Un enfoque clínico-patológico. Dermatol Rev Mex 1991;35:292-300.
9. Manzanera GA. Nevos melanocíticos, coorrelación clínico patológica. Tesis de posgrado. Centro Dermatológico Pascua, 1980.
10. Mireles RH. Dermatoscopia. México: Ediciones Medicina y Cultura, 1996: 15-65.
11. Peniche J. Tumores de la piel. Lecciones de Dermatología. Saúl A. México: Méndez Editores 1993:445-495.
12. Perry Pepper OH. Medical Etymology. Philadelphia London: W.B. Saunders Company, 1954:197.
13. Pinkus H, Meehregan A. A guide
to Dermatohistopathology. NewYork: Appleton-Century-Crofts, 1976: 435-442.
14. Rook A, Wilkinson DS, Ebling FJG,
el al. Tratado de Dermatología. Barcelona España: Ediciones Doyma, S.A. 1989:185-211.
15. Ruiz-Maldonado R, Tamayo L. Laterza AM, et al. Giant pigmented nevi:clinical, histopathological, and therapeutic considerations. J Pediatr 1992; 120:906-911.
16. Ruiz-Maldonado R, Barona Mazuera M. Del Refugio, Hidalgo – Galván LR, et al. Giant congenital melanocytic nevi, neurocutaneous melanosis and neurological alterations. Dermatology 1997;195:125-128.
17. Ruiz-Maldonado R. Saturated phenol as a local anesthetic for manual dermabrasión. Dermatol Surg 1997; 23:187-190
18. Segers AM, Kaminsky A. Melanoma y nevus cutáneos. Prens Med Arg 1959;46:1979.
19. Skender T, Heenan P. Benign melano- cytic lesions: Risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995;33:1000-1007.
20. Sierra VX. El dermatólogo y el lenguaje. Piel 1995;10:167-169.
21. Sierra X. ¿A qué llamamos nevus? Piel 1996;11:391-392.
22. Silva Sergio, Hermosilla Eduardo. Lesiones pigmentadas en la infancia. Pontificia Universidad Católica de Chile 2001.

DERMATOSIS PRECANCEROSAS

1. Arenas R. Dermatología, Atlas, diagnóstico y tratamiento. 2a ed México D.F.: McGraw-Hill;1996.p 541-547.
2. Black H, Herd A, Golderg L, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994;330:1272-1275.
3. Black HS. Influence of dietary factors on actinically-induced skin cancer. Mutation Research/fundamental and molecular mechanisms of mutagenesis 1998; 422 (abstract): 185-190.
4. Brash DE, Ponten J. Skin precancer. Cancer Surv 1998;32(abstract):69-113.
5. Chu and Edelson. Malignant tumors of the skin. 1era ed. London: Arnold; 1999. p 33-39 (Fig 2.13).
6. Cockerell C. Histopathology of incipient intraepidermal cutaneous squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000; 42:S11-S17.
7. Dinehart S. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42:S25-S28.
8. Dufresne R, Curlin M. Actinic Cheilitis. Dermatol Surg 1997;23:15-21.
9. Epidemiology of solar keratosis. Br J Dermatol 1994;151:455-464.
10. Fazel N, Wilczynski S, Lowe L, et al. Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Clin Dermatol 1999;17:521.
11. Fitzpatrick TB. Dermatology en General Medicine 5th ed. New York. MacGraw-Hill. 1999:823-839.
12. Guenthner S, Hurwitz R, Buckel L. Cutaneous squamous cell carcinoma consistently show histologic evidence of in situ changes: A clinicopathologic correlation. J Am Acad Dermatol 1999;41:443-448.
13. Habif T. Clinical Dermatology A
Color Guide to Diagnosis and Therapy. 3rd ed. Mosby-Year Book, Inc.; 1996. p 670.
14. Heaphy MR, Ackerman A. The nature of solar keratosis. A critical review in historical perspective. J Am Acad Dermatol 2000;43:138-150.
15. Jeffes EW. Actinic keratosis: Current treatment options. Am J Clin Dermatol 2000;13(abstract):167-179.
16. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000;42:389-413.
17. Khavari P, Krueger G. Cutaneous gene therapy. Dermatol Clin 1997; 15:27-35.
18. Kubo Y, Urano Y, Yoshimoto K, et al. P53 gene mutations in human skin cancers and precancerous lesiones: Comparison with immunohistochemical analysis. J Invest Dermatol 1994;102:440-444.
19. Moy RL. Clinical presentation of actinic keratosis and squamous cell carcinoma. J Am Acad Dermatol 2000: 42:S8-S10.
20. Naylor M, Farmer K. The case for Sunscreens. Arch Dermatol 1997: 133:1146-1154.
21. Nomura T, Nakajima H, Hongyo T, et al. Induction of cancer, actinic keratosis, and specific p53 mutations by UVB light in human skin maintained in severe combined immunodeficient mice. Cancer Res 1997; 57(abstract): 2081-2084.
22. Peniche J. Dermatosis precancerosas. En : Saúl A. lecciones de dermatología. México Méndez; 1993. p 469-473.
23. Plasencia JM. Cutaneous Warts. Prim Care 2000;27:433-434.
24. Raskin C. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997; 36: 885-896.
25. Rehman I, Quinn AG, Healy E, et al. High frecuency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 1994; 344:788-789.
26. Rivers J, McLean D. An Open Study to assess the efficacy and safety of topical 3% diclofenac in 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133:1239-1242.
27. Rodríguez M. Tesis de posgrado en Dermatología,Leprología y Micología. Centro Dermatológico Pascua. Tratamiento de queratosis actínicas con 5-Fluoracilo combinado con criocirugía. México D.F. 1998.
28. Stuart J Salasche. Epidemiology of actinic keratosis and squamous cell carcinoma. J Am Acad Dermatol 2000;42:S4-S7.
29. Taguchi M, Watanabe S, Yashima K, et al. Abberrations of the tumor suppresor p53 gene and p53 protein in solar keratosis in human skin. J Invest Dermatol 1994;103:500-503.
30. Yantsos VA, Conrad N, Zabawsid E, et al. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Sem Cutan Med Surg 1999;18(abstract):3-14.
31. Zlegler A, Jonason A, Leffell D et al. Sunburn an p53 in the onset of skin cancer. Nature 1994;372:773-776.

CARCINOMA BASOCELULAR

1. Beutner KR, Geisse Jk, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-1007.
2. Cordovés B y Peniche J (Asesor de tesis). Estudio retrospectivo de 1,235 carcinomas basocelulares. Tesis de Posgrado en Dermatología. UNAM 1988.
3. Grosshans E. Carcinomes Basocellulaires. Encycl Med Chir (Eisevier, Paris) Dermatologie 98-620-A-10, 1999. p 8.
4. Lang PG and Maize JC. Basal cell carcinoma. In: Friedman RJ, Rigel DS, Kopf AW, et al. Cancer of the skin. WB Saunders, Philadelphia, 1991. p 35-73.
5. Menaker GM, Chiu DS. Basal cell carcinoma. In: Sober AJ and Haluska FG. Skin cancer. American Cancer Society. BC Decker Inc. Hamilton, Ontario, 2001. p 60-71.
6. Mikkilineni R, Weinstock MA. Epidemiología. In Sober AJ and Haluska FG. Skin cancer. American Cancer Society. BC Decker Inc. Hamilton, Ontario, 2001. p 1-15.
7. Munn S, Basarab T and Chu T. Basal cell carcinomas. In: Chu AC and Edelson RL. Malignant tumors of the skin. Arnold, London, 1999. p 1-18.
8. Peniche J, Albores-Saavedra J. Quimioterapia local del cáncer cutáneo con 5-fluorouracilo. Rev Mex Dermatol1968;12:137.
9. Ramírez-Tamayo T, Peniche J y León G (asesores de tesis). Carcinoma Basocelular. Estudio retrospectivo de 1527 casos. Tesis de diplomado en Dermatooncología y Cirugía Dermatológica. Hospital General de México, O.D. 2000.
10. Registro Histopatológico de Neoplasias en México. DGE. Secretaría de Salud. Morbilidad 1993-1997. Mortalidad 1987-1997.
11. Registro Histopatológico de Neoplasias en México. DGE. Secretaría de Salud 1998.
12. Thissen MRTM, Neumann MHA, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-1183.
13. Urbano Y, Asamo T, Yoshimoto K. Frecuent P53 accumulation in the chronically sun-exposed epidermis adjacent to basal cell carcinoma. J Invest Dermatol 1995;104:928-932.
14. Urbach F. Incidence of non melanoma skin cancer. Dermatologics Clinics October 1999;9(4):751-755.

CARCINOMA EPIDERMOIDE

1. Degos R Tumeurs malignes. En: Degos R. Dermatologie. Paris, Flammarion Medicines-Sciences,; 1953. p 831-863.
2. Fisher MS, Kripke ML. Suppressor T lymphocytes control in the development of primary skin cancers in ultraviolet –irradiated mice. Science 1982;216:1133-1134.
3. Forman AB, Roenigk HH, Caro WA. Long-term follow- up of skin canacer in then PUVA-48 cooperative study. Archives of Dermatology 1989:125.
4. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989; 262:2097-2100.
5. Gloster HM, Brodland DG. The
epidemiology of skin cancer. Dermatological Surgery, 1996;22:217-226.
6. Grosshans E. Les epitheliomas cutanes. En: Moreau L. Encyclopedie Medico-Chirurgicale. Paris: In Moreau L; 1989. p 12750 A10.
7. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Archives of Dermatology 1986; 122:1288-1293.
8. Hersey P, Haran G, Hrsec E, et al. Alteration of T cell subsets and induction o suppressor T cell activity in normal subjects after exposure to sunlight. Journal of immunology 1983;131:171-174.
9. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip an oral mucosa). Journal of the American Academy of Dermatology 1992; 26:467-484.
10. Kubo Y, Urano Y, Yoshimoto K, Iwahana H, Fukuhara K, Arase S, Ita kura M. P 53 Gene Mutations in Human skin cancers and precancerous lesions: Comparison with inmunohistochemical Analysis. Journal of Investigative Dermatology 1994; 102:440-444.
11. Miller DL, Weinstock MA. Non-melanoma skin cancer in the United States: incidence. Journal of the American Academy of Dermatology 1994;30:774-778.
12. Peniche J. Tumores de la piel. En: Saul A. Lecciones de Dermatología. 14 va edición México, D.F.: Mendez Cervantes Editores; 2000. p 539-592.
13. Penn I. Inmunosupression and skin cancer. Clinic Plastic Surg 1980; (7):361-368.
14. Preston DS, Stern RS. Non- melanoma cancers of the skin. New England J Med 1992;327:1649-1662.
15. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis and survival rate in squamous cell carcinoma of the skin , ear and lip: implications for treatment modality selection. J Amer Acad Dermatol 1989;20:123-127.
16. Stern RS, Lange R. Non- Melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988;91:120-124.
17. Urbach F. Incidence of Non-melanoma skin cancer. Dermatologic Clinics 1991;9:751-755.
18. Vitaliono PP, Urbach F. The relative importance of risk factors in non-melanoma skin cancer. Arch Dermatology 1980;116:454-456.
19. Yushpa SH .Cutaneous chemical carcinogenesis, J Am Acad Dermatol 1986;15:1031-1044.
20. Ziegler A, Jonason AS, Lefell DJ, Simon JA, Sharma HW, Kimmelman LR, Jacks T, Brash DE. Sunburn and P53 in the onset of skin cancer. Nature 1994;372:773-776.

MELANOMA MALIGNO CUTÁNEO

1. Alfeiran Ruiz A, Escobar Alfaro G, De la Barreda Becerril F, et al. Epidemiología del melanoma de piel en México. Revista del Instituto Nacional de Cancerología, 1998;44:168-174.
2. Arellano Mendoza I, Peniche J (Asesor de Tesis). Melanoma Maligno. Estudio epidemiológico de 214 casos observados en el Hospital General de México en los años 1975-1985. Tesis de Posgrado en Dermatología, 1989. Hospital General de México.
3. De la Barreda Becerril F, Alfeiran Ruiz A, Escobar Alfaro G. Melanoma Cutáneo. Revista del Instituto Nacional de Cancerología, 1998; 44:201-204.
4. Fargnoli MC and Bolognia JL. The biology of melanoma. In: Chu and Edelson. Malignant tumors of theskin. Arnold, London, 1999. p 49-65.
5. González Cervantes JG, Mora Tiscareño A, Beltrán Ortega A. 261 casos de melanoma cutáneo. Características generales y factores de valor pronóstico. Revista del Instituto
Nacional de Cancerología, 1990; 36:1103-1112.
6. Grin CM, Kopf AW, Welkovich B, et al. Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol 1990;126:763-766.
7. Hauschild A, Kiene P, Christophers E. Melanoma Clinical. In: Chu and Edelson. Malignant tumors of the skin. Arnold, London, 1999. p 66-77.
8. Langley RG, Barnhill RL, Mihm MC, Fitzpatrick TB, Sober AJ. Cutaneous melanoma. In: Fitzpatrick's Dermatology in General Medicine. McGraw-Hill. Fifth Ed. 1999. p 1080-1116.
9. Langley RG, Mihm MC, Sober AJ. Clinical presentation: Melanoma. In: Sober and Haluska. Skin Cancer. American Cancer Society. BC Decker 2001. p 49-59.
10. Mikkilineni R, Weinstock MA. Epidemiology. In: Sober and Haluska. Skin Cancer. American Cancer Society. BC Decker, 2001. p 1-15.
11. Pineda JA, Peniche J, Leon G, Arellano I (Asesores de Tesis). Factores de riesgo en el melanoma acral lentiginoso. Estudio de casos y controles (1987-1996). Tesis de Posgrado en Dermato-Oncología, 1997. Hospital General de México.
12. Sachs D, Marghoob A, Halpern AC. Risk assessment. In: Sober and Haluska. Skin Cancer. American Cancer Society. BC Decker, 2001. p 31-48.

TRATAMIENTO QUIRÚRGICO DEL CARCINOMA BASOCELULAR Y CARCINOMA EPIDERMOIDE

1. Grande DJ, Ratner D, Stadecker MJ. Basall cell carcinoma. Dermatologic Surgery. Principles and practice. New York: Mancel Dekker, Inc.; 1996. p 489-499.
2. Melton JL, Hanke CW. Squamos Cell Carcinoma. Dermatologic surgery, principles and practice. New York: Mancel Dekker, Inc.; 1996. p 503-518.
3. Roseeuw D, Katsambas AD. Besal Cell Carcinoma. European handbook of dermatological treatments Berlín: Springer-Verlag; 2000. p 75-88.
4. Roseeuw D, Katsambas AD. Squamos Cell Carcinoma. European handbook of dermatological treatments Berlín: Springer-Verlag; 2000. p 545-548.
5. Schwartz RA. Skin Cancer. Dermatol Surg 1997;23:1005-1118.
6. Straten MV, Lee P, Weitzul S, Cockerell CJ, Tyring SK. Advances in the treatment of Basal Cell carcinoma: The promise of pharmacologic therapy. Advances in Dermatology, St. Louis: Mosby, Inc. Mo; 2000. p 16:299-313.

CIRUGÍA MICROGRÁFICA DE MOHS

1. Becker GD, Adams LA, Levin BC. Spontaneous healing of Mohs wound of cheek: a cosmetic assessment. Dermatol Surg 1988;24:1375-1382.
2. Bieley HC, Kirsner RS, Reyes BA et al. The use of mohs micrographic surgery for determination of residual tumor in incompletely excised basal cell carcinoma. J Am Acad Dermatol 1992;26:754-756.
3. Camps-Fresneda A, Umbert MA. Selección de tumores para cirugía de Mohs. Indicaciones para el proceso de reconstrucción. En Camacho F. Monografías de Dermatología. Madrid-España: Jarpyo Editores;1990; 3(4): 239-44.
4. Conrad N, Jackson B, Goldberg L. Amelanotic Lentigo Maligna Melanoma: A unique case presentation. Dermatol Surg 1999;25:408-411.
5. Cook J, Zitelli JA. Mohs micrographic surgery: A cost analysis. J Am Acad Dermatol 1998;39:698-703.
6. Drake LA, Dinehart SM, Goltz RW et al. Guidelines of care for Mohs micrographic surgery. J Am Acad Dermatol 1995;33:271-278.
7. Dzubow LM. Mohs surgery. Lancet 1994;343:433-434.
8. Grekin RC, Geisse JK, Marglis L et al. Malignant neoplasms of keratinocytes:Treatment. En: Arndt KA, LeBoit PE, Robinson JK et al. Cutaneous Medicine and Surgery. W B Philadelphia-USA: Saunders Co.; 1996;2:1393-1408.
9. Imayama S. Morphologic basis for adequate surgical excision of basal cell epitheliomas. Arch Dermatol 1988;124:1715-1716.
10. Kawika WN, Becker DS. Potencial Utility of adjunctive histopathologic evaluation of some tumors treated by Mohs micrographic surgery. Dermatol Surg 2000;26:1052-1056.
11. Larson PO, Snow SN, Mohs FE. Mohs Micrographic Surgery. En Lask GP, Moy RL. Principles and Techniques of Cutaneous Surgery. Mc Graw-Hill. USA. 1996;41:562-578.
12. Lin BB, Taylor RS. Digital photography for mapping Mohs micrographic surgery sections. Dermatol Surg 2001;27:411-4.
13. Mohs FE. Chemosurgery for skin cancer: fixed tissue and fresh tissue techniques. Arch Dermatol 1976; 112:211-215.
14. Ocampo CJ, Golberg LH, Camps FA. Cirugía de Mohs. Su historia, técnica actual y fururo. Revista Mexicana de Dermatología. Segunda época. 1989; 33(2):100-105.
15. Ocampo CJ, Hermosillo ME. Cirugía de Mohs. Experiencia en México: nuestros primeros 100 casos. Piel 1995; 10:60-63.
16. Orengo IF, Salasche SJ, Fewkes J et al. Correlation of histologic of primary basal cell carcinoma and number of Mohs stages required to achieved a tumor-free plane. J Am Acad Dermatol 1997;37:395-401.
17. Pazos CJ. Carcinoma Basocelular. Piel 1999;14:454-65.
18. Ratner D, Thomas CO, Johnson TM et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1997;37:600-613.
19. Robins P. Historia de la Cirugía Micrográfica de Mohs (quimiocirugía). En Camacho F. Monografías de Dermatología. Madrid-España: Jarpyo Editores;1990;3(4):208-13.
20. Shriner DL, Mc Coy DK, Golberg DL. Mohs Micrographic Surgery. J Am Acad Dermatol1988;39:79-97.
21. Suro JA, Labareda J, Themido R y col. Recidivas tardías de carcinoma basocelular después de cirugía de mohs. Med Cután Iber Lat Am 2001;29:40-42.
22. Tromovitch TA, Stegman SJ. Microscopically controlled excision of skin tumors. Arch Dermatol 1974; 110:231-232.
23. Zitelli JA, Hanusa BH. Mohs micrographic surgery for the treatment of primary cu taneous melanoma. J Am Acad Dermatol 1997;37:236-245.

USO DE TERAPIA LÁSER EN DERMATO-ONCOLOGÍA

1. Alster T S. Comparision of two high-energy, pulsed CO2 lásers in the treatment of periorbital rhytides. Dermatol Surg 1996;22:541-545.
2. Alster TS. Manual of cutaneous laser tecniques. Lippincott-Raven publishers, Philadelphia.1997.
3. Alster TS, Apfelberg DB. Cosmetic Láser Surgery. Edit Wileyliss. 1996 New York.
4. Alster TS, West TB. Resurfacing of atrophic facial scars with a high energy pulsed carbon dioxide láser. Dermatol Surg 1996;22:151-155.
5. Alster TS. Improvement or erythematous and hypertrophic scars by the 585 nm pulsed dye laser. Ann Plast Surg 1994;32:186-190.
6. Dover JS, Geronemus RG, Stern RS. Dye laser treatment or port-wine stains: comparision of the continuos-wave dye laser with a robotized scanning device and the pulsed dye láser. J Am Acad Dermatol 1995;32:237-240.
7. Fitzpatrick RE, Goldman MP. Tatoo removal using the alexandrite laser. Arch Dermatol 1994;130:15108-15114.
8. Grossman MC, Diericky C, Farinelli W. Damage to hair follicles by normal-mode ruby láser pulses. J Am Acad Dermatol 1996;35:889-94.
9. Stafford TJ, Lizek R, Boll J, Tan OT. Removal of colored tatoos with the Q-switched alexandrite laser. Plast Reconst Surg 1995;95:313-320.
10. Taylor CR, Anderson RR. Treatment of benign pigmented epidermal lesions by Q-switched ruby láser. Int J Dermatol 1993;32:908-912.
11. Waner M, Yee Suen J, Dinehart S. Laser photocoagulation of superficial proliferating hemangiomas. J Dermatol Surg Oncol 1994;20:43-46.
12. Weston J, Apfelberg DB, Maser MR. Carbon dioxide laser abrasion for treatment of adenoma sebaceum in tuberous sclerosis. Ann Plast Surg 1985;15:132-137.
13. Wheeland RG, ApplebaumJ. Flashlamp-pumped pulsed dye laser theraphy for poikilodermia of Civatte. J Dermatol Surg Oncol 1990;16:12.